Adagene (ADAG) vs AN2 Therapeutics (ANTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Adagene (ADAG) over the past year, gaining 270.2% versus a gain of 41.2%. Adagene is the larger company by market cap ($186.0 million vs $174.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | ANTX |
|---|---|---|
| Share price | $2.77 | $4.63 |
| Market cap | $185.99M | $174.72M |
| 1-day change | -1.42% | -4.53% |
| YTD return | +48.68% | +325.44% |
| 1-year return | +41.21% | +270.23% |
| 5-year return | -75.98% | — |
| EPS (TTM) | $-0.38 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $7.19 |
| 52-week low | $1.30 | $1.00 |
| Distance from 52-week high | -42.89% | -35.61% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +257.76% | +94.38% |
| Average volume | 245.22K | 235.07K |
| Shares outstanding | 67.14M | 37.74M |
| Employees | 128 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed ADAG by 229.0 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
ADAG vs ANTX FAQ
Which is bigger, Adagene or AN2 Therapeutics?
Adagene (ADAG) is larger, with a market capitalization of $185.99M compared with $174.72M for AN2 Therapeutics (ANTX).
Which stock has performed better over the past year, ADAG or ANTX?
ANTX returned +270.23% over the past 12 months, compared with +41.21% for ADAG (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and AN2 Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.